×
About 3,564 results

ALLMedicine™ Bacterial Pneumonia Center

Research & Reviews  1,547 results

Lefamulin (Xenleta) for the Treatment of Community-Acquired Bacterial Pneumonia.
https://www.ncbi.nlm.nih.gov/pubmed/32931220
American Family Physician; Felix TM, Karpa K

Sep 15th, 2020 - Lefamulin (Xenleta) for the Treatment of Community-Acquired Bacterial Pneumonia.|2020|Felix TM,Karpa K,|

Five-Day Antibiotic Treatment for Community-Acquired Bacterial Pneumonia: A Systematic ...
https://doi.org/10.1016/j.jgar.2020.08.005
Journal of Global Antimicrobial Resistance; Lan SH, Lai CC et. al.

Aug 31st, 2020 - This systematic review and meta-analysis of randomized controlled trials (RCTs) investigated whether the clinical efficacy of a 5-day antibiotic course is comparable to that of a longer (≥7 d) course for treating adults with community-acquired bac...

Chest complications in immunocompromised patients without acquired immunodeficiency syn...
https://doi.org/10.1016/j.crad.2020.07.029
Clinical Radiology; Tanaka N, Kunihiro Y et. al.

Aug 24th, 2020 - To differentiate between infectious and non-infectious diseases occurring in immunocompromised patients without acquired immunodeficiency syndrome (AIDS) using high-resolution computed tomography (HRCT). HRCT images of 555 patients with chest comp...

An Open-Label Study of the Impact of Hepatic Impairment on the Pharmacokinetics and Saf...
https://doi.org/10.1128/AAC.01650-20
Antimicrobial Agents and Chemotherapy; Kovacs SJ, Ting L et. al.

Aug 23rd, 2020 - Omadacycline is a once-daily oral or intravenous (IV) aminomethylcycline antibiotic approved in the United States for treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) in adu...

Parasitic Infection Misdiagnosed As Bacterial Pneumonia: A Case Report.
https://www.ncbi.nlm.nih.gov/pubmed/32827408
Alternative Therapies in Health and Medicine; Yang X, Leng T et. al.

Aug 22nd, 2020 - Bacterial pneumonia is a common lung disorder, and the pathogenesis remain elusive. Parasitic infections of the lung are able to affect the respiratory system, and the clinical features could mimic tuberculosis and malignancy. Therefore, it is ess...

see more →

Guidelines  7 results

Shared Decision-Making for Administering PCV13 in Older Adults
https://www.aafp.org/afp/2020/0201/p134.html
American Family Physician; Shah AA,et al

Jan 31st, 2020 - Streptococcus pneumoniae infection, the most common cause of bacterial pneumonia, leads to significant morbidity and mortality in older people. With the addition of the pneumococcal conjugate vaccine to childhood immunization schedules in 2000, he...

Melinta Therapeutics Announces U.S. FDA Approval of Supplemental New Drug Application for BAXDELA® (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)
http://ir.melinta.com/news-releases/news-release-details/melinta-therapeutics-announces-us-fda-approval-supplemental-new

Oct 23rd, 2019 - Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced the U.S. Food and Drug Administration (FDA) has appr...

Improving Conduct and Feasibility of Clinical Trials to Evaluate Antibacterial Drugs to...
https://doi.org/10.1093/cid/ciw258
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America; Knirsch C, Alemayehu D et. al.

Aug 2nd, 2016 - The etiology of hospital-acquired or ventilator-associated bacterial pneumonia (HABP/VABP) is often multidrug-resistant infections. The evaluation of new antibacterial drugs for efficacy in this population is important, as many antibacterial drugs...

Streamlining Safety Data Collection in Hospital-Acquired Bacterial Pneumonia and Ventil...
https://doi.org/10.1093/cid/ciw316
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America; Donnelly H, Alemayehu D et. al.

Aug 2nd, 2016 - Resistant bacteria are one of the leading causes of hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP). HABP/VABP trials are complex and difficult to conduct due to the large number of medical procedures, adverse events, and c...

XENLETA™ (lefamulin) Website for Healthcare Professionals
https://www.xenleta.com/

community-acquired bacterial pneumonia See XENLETA™ (lefamulin) clinical trial results and product attributes

see more →

Drugs  131 results see all →

Clinicaltrials.gov  1,745 results

Lefamulin (Xenleta) for the Treatment of Community-Acquired Bacterial Pneumonia.
https://www.ncbi.nlm.nih.gov/pubmed/32931220
American Family Physician; Felix TM, Karpa K

Sep 15th, 2020 - Lefamulin (Xenleta) for the Treatment of Community-Acquired Bacterial Pneumonia.|2020|Felix TM,Karpa K,|

Five-Day Antibiotic Treatment for Community-Acquired Bacterial Pneumonia: A Systematic ...
https://doi.org/10.1016/j.jgar.2020.08.005
Journal of Global Antimicrobial Resistance; Lan SH, Lai CC et. al.

Aug 31st, 2020 - This systematic review and meta-analysis of randomized controlled trials (RCTs) investigated whether the clinical efficacy of a 5-day antibiotic course is comparable to that of a longer (≥7 d) course for treating adults with community-acquired bac...

Zerbaxa - ceftolozane and tazobactam injection, powder, lyophilized, for solution-Merck Sharp & Dohme Corp.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70ac1d90-eff3-4f0b-9f46-5846c571b32f

Aug 31st, 2020 - ZERBAXA (ceftolozane and tazobactam) is a combination of ceftolozane, a cephalosporin antibacterial, and tazobactam, a beta-lactamase inhibitor, indicated in patients 18 years or older for the treatment of the following infections caused by design...

Chest complications in immunocompromised patients without acquired immunodeficiency syn...
https://doi.org/10.1016/j.crad.2020.07.029
Clinical Radiology; Tanaka N, Kunihiro Y et. al.

Aug 24th, 2020 - To differentiate between infectious and non-infectious diseases occurring in immunocompromised patients without acquired immunodeficiency syndrome (AIDS) using high-resolution computed tomography (HRCT). HRCT images of 555 patients with chest comp...

An Open-Label Study of the Impact of Hepatic Impairment on the Pharmacokinetics and Saf...
https://doi.org/10.1128/AAC.01650-20
Antimicrobial Agents and Chemotherapy; Kovacs SJ, Ting L et. al.

Aug 23rd, 2020 - Omadacycline is a once-daily oral or intravenous (IV) aminomethylcycline antibiotic approved in the United States for treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) in adu...

see more →

News  131 results

Shared Decision-Making for Administering PCV13 in Older Adults
https://www.aafp.org/afp/2020/0201/p134.html
American Family Physician; Shah AA,et al

Jan 31st, 2020 - Streptococcus pneumoniae infection, the most common cause of bacterial pneumonia, leads to significant morbidity and mortality in older people. With the addition of the pneumococcal conjugate vaccine to childhood immunization schedules in 2000, he...

Melinta Therapeutics Announces U.S. FDA Approval of Supplemental New Drug Application for BAXDELA® (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)
http://ir.melinta.com/news-releases/news-release-details/melinta-therapeutics-announces-us-fda-approval-supplemental-new

Oct 23rd, 2019 - Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced the U.S. Food and Drug Administration (FDA) has appr...

Lefamulin found noninferior to moxifloxacin for bacterial pneumonia
https://www.mdedge.com/pulmonary-health-hub/article/209198/infectious-diseases/lefamulin-found-noninferior-moxifloxacin?channel=94
Heidi Splete

Oct 1st, 2019 - Persistent high rates of bacterial resistance to current treatments have created the need for more options, especially for the treatment of community-acquired bacterial pneumonia (CABP), which remains a leading cause of hospitalization and death i.

Years ago, this doctor linked a mysterious lung disease to vaping
https://www.mdedge.com/pediatrics/article/206955/pulmonology/years-ago-doctor-linked-mysterious-lung-disease-vaping/page/0/1?channel=27980

Aug 23rd, 2019 - We really felt that it wasn’t going to be a one-off event and that it was what we usually called in public health a “sentinel” health event … that it was an example of a respiratory illness that can be caused by this exposure and that it probably.

FDA approves lefamulin for community-acquired bacterial pneumonia treatment
https://www.mdedge.com/chestphysician/article/206944/pulmonology/fda-approves-lefamulin-community-acquired-bacterial?channel=284
Lucas Franki, MDedge News

Aug 20th, 2019 - The Food and Drug Administration has announced its approval of lefamulin (Xenleta) for the treatment of community-acquired bacterial pneumonia in adults. Olivier Le Moal/Getty Images Approval was based on results of two clinical trials assessing a.

see more →

Patient Education  3 results see all →